Crossmark

Structure-guided combination therapy to potently improve the function of mutant CFTRs

Crossref DOI link: https://doi.org/10.1038/s41591-018-0200-x

Published Online: 2018-10-08

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Veit, Guido http://orcid.org/0000-0002-6758-2696
Xu, Haijin

Dreano, Elise

Avramescu, Radu G.

Bagdany, Miklos

Beitel, Lenore K.

Roldan, Ariel

Hancock, Mark A.

Lay, Cecilia

Li, Wei

Morin, Katelin

Gao, Sandra

Mak, Puiying A.

Ainscow, Edward

Orth, Anthony P.

McNamara, Peter

Edelman, Aleksander

Frenkiel, Saul

Matouk, Elias

Sermet-Gaudelus, Isabelle

Barnes, William G.

Lukacs, Gergely L.
License Information

Text and Data Mining valid from 2018-10-08
More Information

Article History

Received: 28 August 2017

Accepted: 8 August 2018

First Online: 8 October 2018

Competing interests

: C.L., W.L., K.M., S.G., P.A.M., F.J.K., E.A., A.J.O., P.M. and W.G.B. are employees of the Genomics Institute of the Novartis Research Foundation. I.S.-G. has been principal investigator in Vertex initiated clinical trials, received a Vertex Pharmaceuticals Innovation Award and served as a scientific advisory board member for Vertex Pharmaceuticals. G.L.L. is a member of the Scientific Advisory Board of Proteostasis Therapeutics Inc. All other authors declare no competing financial or non-financial interests.